Saladax Expands Relationship with BMS

Saladax Biomedical has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement.

Saladax Biomedical, Inc. has expanded its existing relationship with Bristol-Myers Squibb Company by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. 

With the signing of this agreement, the companies have already initiated a new companion diagnostic project in an undisclosed field. 

"Saladax is delighted to continue working with Bristol-Myers Squibb to deliver on the promise of personalized medicine," said Kevin M. Harter, president and CEO of Saladax.  "Building on our previous work together, which resulted in clinically valuable Alzheimer's disease assays, we're eager to continue marrying the scie